A recent meta-analysis has suggested that adding docetaxel to ADT and radiation significantly reduces PCSM in patients with high-grade, non-metastatic, treatment-naïve prostate cancer with low PSA levels, particularly in those with good performance status [18]. Here, KLK3 is linked to prostate carcinoma.